|
1
|
Parkin M, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Stein JP, Lieskovsky G, Cote R, et al:
Radical cystectomy in the treatment of invasive bladder cancer:
long-term results in 1,054 patients. J Clin Oncol. 19:666–675.
2001.PubMed/NCBI
|
|
3
|
Netto G and Epstein J: Theranostic and
prognostic biomarkers: genomic applications in urological
malignancies. Pathology. 42:384–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Altomare D and Testa J: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sherr C and Roberts J: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Azim H, Azim H and Escudier B: Targeting
mTOR in cancer: renal cell is just a beginning. Target Oncol.
5:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mass R, Press M, Anderson S, et al:
Evaluation of clinical outcomes according to HER2 detection by
fluorescence in situ hybridization in women with metastatic breast
cancer treated with trastuzumab. Clin Breast Cancer. 6:240–246.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Graff JR, Konicek BW, McNulty AM, et al:
Increased AKT activity contributes to prostate cancer progression
by dramatically accelerating prostate tumor growth and diminishing
p27Kip1 expression. J Biol Chem. 275:24500–24505. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merseburger A, Hennenlotter J, Kuehs U, et
al: Activation of PI3K is associated with reduced survival in renal
cell carcinoma. Urol Int. 80:372–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hennenlotter J, Ohneseit P, Simon P, et
al: PTEN and p27Kip1 are not downregulated in the majority of renal
cell carcinomas – implications for Akt activation. Oncol Rep.
19:1141–1147. 2008.
|
|
12
|
Kurose K, Zhou X-P, Araki T, Cannistra S,
Maher E and Eng C: Frequent loss of PTEN expression is linked to
elevated phosphorylated Akt levels, but not associated with p27 and
cyclinD1 expression, in primary epithelial ovarian carcinomas. Am J
Pathol. 158:2097–2106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kallioniemi OP, Wagner U, Kononen J and
Sauter G: Tissue microarray technology for high-throughput
molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Theodorescu D, Broder SR, Boyd JC, Mills
SE and Frierson HF: Cathepsin D and chromogranin A as predictors of
long term disease specific survival after radical prostatectomy for
localized carcinoma of the prostate. Cancer. 80:2109–2119. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Blain S, Scher H, Cordon-Cardo C and Koff
A: p27 as a target for cancer therapeutics. Cancer Cell. 3:111–115.
2003. View Article : Google Scholar
|
|
16
|
Chiarle R, Pagano M and Inghirami G: The
cyclin dependent kinase inhibitor p27 and its prognostic role in
breast cancer. Breast Cancer Res. 3:91–94. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seki R, Ohshima K, Fujisaki T, et al:
Prognostic significance of S-phase kinase-associated protein 2 and
p27kip1 in patients with diffuse large B-cell lymphoma: effects of
rituximab. Ann Oncol. 21:833–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Panigrahi AR, Pinder SE, Chan SY, Paish
EC, Robertson JFR and Ellis IO: The role of PTEN and its signalling
pathways, including AKT, in breast cancer; an assessment of
relationships with other prognostic factors and with outcome. J
Pathol. 204:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khaleghpour K, Li Y, Banville D, Yu Z and
Shen SH: Involvement of the PI 3-kinase signaling pathway in
progression of colon adenocarcinoma. Carcinogenesis. 25:241–248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi W, Zhang X, Pintilie M, et al:
Dysregulated PTEN-PKB and negative receptor status in human breast
cancer. Int J Cancer. 104:195–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoganathan TN, Costello P, Chen X, et al:
Integrin-linked kinase (ILK): a ‘hot’ therapeutic target. Biochem
Pharmacol. 60:1115–1119. 2000.
|
|
23
|
Persad S, Attwell S, Gray V, et al:
Inhibition of integrin-linked kinase (ILK) suppresses activation of
protein kinase B/Akt and induces cell cycle arrest and apoptosis of
PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA.
97:3207–3212. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Widenmaier S, Sampaio A, Underhill M and
McIntosh C: Noncanonical activation of Akt/protein kinase B in
{beta}-cells by the incretin hormone glucose-dependent
insulinotropic polypeptide. J Biol Chem. 284:10764–10773.
2009.PubMed/NCBI
|
|
25
|
Trotman L, Alimonti A, Scaglioni PP,
Koutcher J, Cordon-Cardo C and Pandolfi PP: Identification of a
tumour suppressor network opposing nuclear Akt function. Nature.
441:523–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blain S and Massagué J: Breast cancer
banishes p27 from nucleus. Nat Med. 8:1076–1078. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Connor M, Kotchetkov R, Cariou S, et al:
CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear
export signal and links p27 export and proteolysis. Mol Biol Cell.
14:201–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang J, Zubovitz J, Petrocelli T, et al:
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and
opposes p27-mediated G1 arrest. Nat Med. 8:1153–1160. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin I, Yakes M, Rojo F, et al: PKB/Akt
mediates cell-cycle progression by phosphorylation of p27Kip1 at
threonine 157 and modulation of its cellular localization. Nat Med.
8:1145–1152. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Capodanno A, Camerini A, Orlandini C, et
al: Dysregulated PI3K/Akt/PTEN pathway is a marker of a short
disease-free survival in node-negative breast carcinoma. Hum
Pathol. 40:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pantuck A, Seligson D, Klatte T, et al:
Prognostic relevance of the mTOR pathway in renal cell carcinoma.
Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen M, Gu J, Delclos G, et al: Genetic
variations of the PI3K-AKT-mTOR pathway and clinical outcome in
muscle invasive and metastatic bladder cancer patients.
Carcinogenesis. 31:1387–1391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shariat S, Ashfaq R, Sagalowsky A and
Lotan Y: Predictive value of cell cycle biomarkers in nonmuscle
invasive bladder transitional cell carcinoma. J Urol. 177:481–487.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Laé M, Couturier J, Oudard S, Radvanyi F,
Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as
a potential target for therapy in invasive urothelial bladder
cancer with a standardized methodology: results in 1005 patients.
Ann Oncol. 21:815–819. 2010.PubMed/NCBI
|
|
35
|
Havaleshko D, Smith SC, Cho H, et al:
Comparison of global versus epidermal growth factor receptor
pathway profiling for prediction of lapatinib sensitivity in
bladder cancer. Neoplasia. 11:1185–1193. 2009.PubMed/NCBI
|
|
36
|
Miyake M, Ishii M, Koyama N, et al:
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea
(PD173074), a selective tyrosine kinase inhibitor of fibroblast
growth factor receptor-3 (FGFR3), inhibits cell proliferation of
bladder cancer carrying the FGFR3 gene mutation along with
up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther.
332:795–802. 2010.
|
